Impact of eculizumab on indicators of hemolysis in 13 patients with CAD
| Laboratory test . | Normal range . | Week 0 . | Week 26 . | P . |
|---|---|---|---|---|
| Lactate dehydrogenase, U/L | 120-247 | 572 (534-685) | 334† (243-567) | .0215* |
| Free hemoglobin, mg/dL | <22 | 46.2 (18.2-124.0) | 30.0 (19.5-80.6) | .8438 |
| Bilirubin, µmol/L | 5.1-20.5 | 46.0 (34.2-68.4) | 43.0 (20.0-61.6) | .0117 |
| Haptoglobin, g/L | 0.3-2.0 | 0.04 (0.03-0.05) | 0.03 (0.02-0.05) | .8438 |
| Hemopexin, g/L | 0.5-1.2 | 0.47 (0.18-0.58) | 0.85 (0.45-1.09) | .0127 |
| Hemoglobin, g/dL | 11.6-16.1 | 9.35 (8.80-10.80) | 10.15 (9.00-11.35) | .0391 |
| Reticulocytes, ×109/L | 22-76 | 160.2 (99.1-185.5) | 111.7 (67.4-142.6) | .0625 |
| Laboratory test . | Normal range . | Week 0 . | Week 26 . | P . |
|---|---|---|---|---|
| Lactate dehydrogenase, U/L | 120-247 | 572 (534-685) | 334† (243-567) | .0215* |
| Free hemoglobin, mg/dL | <22 | 46.2 (18.2-124.0) | 30.0 (19.5-80.6) | .8438 |
| Bilirubin, µmol/L | 5.1-20.5 | 46.0 (34.2-68.4) | 43.0 (20.0-61.6) | .0117 |
| Haptoglobin, g/L | 0.3-2.0 | 0.04 (0.03-0.05) | 0.03 (0.02-0.05) | .8438 |
| Hemopexin, g/L | 0.5-1.2 | 0.47 (0.18-0.58) | 0.85 (0.45-1.09) | .0127 |
| Hemoglobin, g/dL | 11.6-16.1 | 9.35 (8.80-10.80) | 10.15 (9.00-11.35) | .0391 |
| Reticulocytes, ×109/L | 22-76 | 160.2 (99.1-185.5) | 111.7 (67.4-142.6) | .0625 |
Values are displayed as median (interquartile range [IQR]) unless otherwise noted.
For the primary end point “lactate dehydrogenase” statistical analysis was done after imputation of missing values for week 26 (P = .0537 without imputation); all other analyses were done without imputation of missing values (see “Methods”).